Vertex, Inc. Announces Pricing of Upsized $300 Million Convertible Senior Notes Offering

10h ago, source:

Vertex, Inc. (NASDAQ: VERX) (“Vertex”), a leading global provider of indirect tax solutions, today announced the pricing of ...

Would I Buy Vertex Inc (NASDAQ: VERX) Stock At Any Time In The Future?

19h ago, source:

The trading price of Vertex Inc (NASDAQ:VERX) floating lower at last check on Tuesday, April 23, closing at $27.65, -7.96% ...

Vertex to Pay $4.9 Billion for Kidney Disease Drug Developer

on MSN ago, source:

Vertex Pharmaceuticals Inc. agreed to buy Alpine Immune Sciences Inc. for a total equity value of about $4.9 billion, adding ...

Vertex Selected to Join Oracle ISV Accelerator for SaaS Initiative

34m ago, source:

Vertex offers customers an optimized business operations and outcomes experience by integrating tax in and around Oracle ...

Cracking The Code: Understanding Analyst Reviews For Vertex

17h ago, source:

In the assessment of 12-month price targets, analysts unveil insights for Vertex, presenting an average target of $38.3, a high estimate of $45.00, and a low estimate of $32.00. Surpassing the ...

Vertex Pharma’s $4.9 billion takeover of Alpine Immune gives it access to a potential billion-dollar franchise, analyst says

on MSN ago, source:

Vertex Pharmaceuticals Inc.’s $4.9 billion acquisition of Alpine Immune Sciences Inc. makes strategic sense and will bolster ...

Vertex Pharmaceuticals Inc VRTX

1d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Vertex to acquire Seattle biotech for $4.9B

13d ago, source:

Vertex Pharmaceuticals Inc. has agreed to buy a Seattle-based biotech developing a drug to treat kidney disease for $4.9 ...

Vertex’s stock climbs as non-opioid pain treatment advances

on MSN ago, source:

Vertex Pharmaceuticals shares gained ground early Thursday after the company signaled progress in the development of its ...

Vertex Pharma obtains exclusive license to TreeFrog's C-Stem to optimize production of its cell therapies for type 1 diabetes

3h ago, source: Pharmabiz

Vertex Pharma obtains exclusive license to TreeFrog's C-Stem to optimize production of its cell therapies for type 1 diabetes: Boston Wednesday, April 24, 2024, 15:00 Hrs [IST] Ve ...

Maintaining Hold on Vertex: Steady Performance with Awaited Earnings Call Insights

1d ago, source:

In a report released yesterday, Samad Samana from Jefferies maintained a Hold rating on Vertex (VERX – Research Report), with a price ...